Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) shares gapped up before the market opened on Wednesday . The stock had previously closed at $14.46, but opened at $14.97. Day One Biopharmaceuticals shares last traded at $14.69, with a volume of 204,907 shares trading hands.
Analyst Upgrades and Downgrades
DAWN has been the topic of a number of recent research reports. JPMorgan Chase & Co. cut their price target on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 6th. Wedbush reissued an "outperform" rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, July 25th. Piper Sandler reissued an "overweight" rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Monday, July 8th. HC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, August 1st. Finally, Needham & Company LLC increased their price target on shares of Day One Biopharmaceuticals from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, October 9th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $35.71.
Read Our Latest Stock Analysis on Day One Biopharmaceuticals
Day One Biopharmaceuticals Price Performance
The stock has a market cap of $1.25 billion, a price-to-earnings ratio of -5.72 and a beta of -1.51. The stock's 50-day moving average is $14.10 and its 200-day moving average is $14.37.
Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.70. The business had revenue of $8.19 million for the quarter, compared to analysts' expectations of $0.90 million. Analysts predict that Day One Biopharmaceuticals, Inc. will post -1.68 EPS for the current fiscal year.
Insider Activity
In other news, insider Samuel C. Blackman sold 2,232 shares of Day One Biopharmaceuticals stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $31,248.00. Following the transaction, the insider now directly owns 1,127,535 shares of the company's stock, valued at $15,785,490. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, General Counsel Adam Dubow sold 3,202 shares of the stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $44,828.00. Following the completion of the sale, the general counsel now owns 26,928 shares in the company, valued at approximately $376,992. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Samuel C. Blackman sold 2,232 shares of the business's stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $31,248.00. Following the transaction, the insider now directly owns 1,127,535 shares in the company, valued at $15,785,490. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 48,748 shares of company stock valued at $689,072 in the last ninety days. Company insiders own 8.40% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new position in Day One Biopharmaceuticals in the 2nd quarter worth $113,000. Point72 DIFC Ltd purchased a new stake in Day One Biopharmaceuticals during the 2nd quarter worth approximately $124,000. Hsbc Holdings PLC acquired a new position in shares of Day One Biopharmaceuticals in the 2nd quarter valued at approximately $163,000. SteelPeak Wealth LLC purchased a new position in shares of Day One Biopharmaceuticals during the 2nd quarter valued at approximately $218,000. Finally, Bayesian Capital Management LP acquired a new stake in shares of Day One Biopharmaceuticals during the first quarter worth approximately $221,000. 87.95% of the stock is owned by institutional investors and hedge funds.
Day One Biopharmaceuticals Company Profile
(
Get Free Report)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Featured Articles
Before you consider Day One Biopharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.
While Day One Biopharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
